 |
53 Diseases |  |
0 Trials |
|
0 Trials |  |
75 News |  |
- || Apolactoferrin (talactoferrin alfa) / Agennix
Clinical, Journal: A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults. (Pubmed Central) - Oct 28, 2024
P=N/A
Recombinant human lactoferrin (rhLF) is of commercial interest for immune support as a food ingredient...Changes in safety outcomes were similar between groups and within normal ranges. These results show that under the conditions of the protocol, no increased anti-hLF antibodies or adverse events were identified following ingestion of effera
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: The [(bathophenanthroline)3:Fe2+] complex as an aromatic non-polymeric medium for purification of human lactoferrin. (Pubmed Central) - Aug 21, 2024
We describe a non-chromatographic, ligand-free platform for the efficient purification of recombinant human lactoferrin (LF)...We provide evidence that protein capture relies on [cation:?] interactions between the lysine and arginine residues of LF with the fully aromatic [(batho)3:Fe2+] complexes. The use of [metal:chelator] complex aggregates is demonstrated to provide an economical and efficient avenue for LF purification.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Evaluation of the potential food allergy risks of human lactoferrin expressed in Komagataella phaffii. (Pubmed Central) - Aug 8, 2024
The use of [metal:chelator] complex aggregates is demonstrated to provide an economical and efficient avenue for LF purification. The allergenic risk potential of Helaina recombinant human lactoferrin (rhLF, Effera
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Digestive Profiles of Human Milk, Recombinant Human and Bovine Lactoferrin: Comparing the Retained Intact Protein and Peptide Release. (Pubmed Central) - Jul 31, 2024
No recombinant human lactoferrin (rhLF) is available for commercial food use...Peptides identified in digested hmLF samples strongly correlated with digested rhLF samples (0.86 < r < 0.92 in the gastric phase and 0.63 < r < 0.70 in the intestinal phase), whereas digested bLF samples were significantly different. These findings support the potential for rhLF as a food ingredient for human consumption.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Workshop Report: A Study Roadmap to Evaluate the Safety of Recombinant Human Lactoferrin Expressed in Komagataella phaffii Intended as an Ingredient in Conventional Foods - Recommendations of a Scientific Expert Panel. (Pubmed Central) - Jul 11, 2024
Relevant workshop topics included physicochemical properties of LF, regulatory history of bovine LF and rhLF as food ingredients in the FDA's generally recognized as safe (GRAS) program, and synopses of publicly available studies on the immunogenicity/alloimmunization, immunotoxicology, iron homeostasis, and absorption, distribution, metabolism, and excretion of rhLF. Panelists concluded that the safety study roadmap addresses the unanswered safety questions and the intended safe use of rhLF as a food ingredient and agreed on broad applications of the roadmap to assess the safety and support GRAS of other recombinant milk proteins with immunomodulatory functions.
- || Apolactoferrin (talactoferrin alfa) / Agennix
Review, Journal: A Review of the Safety Evidence on Recombinant Human Lactoferrin for Use as a Food Ingredient. (Pubmed Central) - Jun 13, 2024
However, no human studies evaluated the immunomodulatory potential of rhLF as a measure of safety. Following this review, a roadmap outlining preclinical and clinical studies with relevant safety endpoints was developed to address the unanswered safety questions.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Characterization of recombinant human lactoferrin expressed in Komagataella phaffii. (Pubmed Central) - May 30, 2024
Following this review, a roadmap outlining preclinical and clinical studies with relevant safety endpoints was developed to address the unanswered safety questions. Differential scanning calorimetry investigations into the thermal stability of Helaina rhLF revealed two distinct denaturation temperatures at 68.7
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii. (Pubmed Central) - Apr 22, 2024
Quantitative LF levels were also analyzed as an indication of bioavailability. Overall, administration of Helaina rhLF by once daily oral gavage for 14
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: New Horizons of Covalent Complex of Plant-Derived Recombinant Human Lactoferrin (OsrhLF) Combined with Different Polyphenols: Formation, Physicochemical Properties, and Gastrointestinal Fate. (Pubmed Central) - Feb 8, 2024
LF-polyphenol emulsions significantly enhanced the photochemical stability and bioavailability of lycopene and achieved effective encapsulation and protection of lycopene compared to free lycopene, and the OsrhLF-EGCG reached 58.94% lycopene bioavailability. In short, OsrhLF does not differ much from bLF in terms of physicochemical properties and has a strong potential in the field of dietary supplements.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Study of pH and Thermodynamic Parameters via Circular Dichroism Spectroscopy of a Recombinant Human Lactoferrin. (Pubmed Central) - Jan 30, 2024
Thermodynamic parameters such as ?H, ?S and Tm were calculated and compared with commercial human lactoferrin. We propose the potential use of CD and thermodynamic parameters as a criterion in the production of recombinant proteins to be used in the production of specialized recombinant proteins.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Expressing recombinant human lactoferrin with antibacterial activity in Nicotiana benthamiana. (Pubmed Central) - Jan 12, 2024
Purified plant-derived rhLF possesses antibacterial activity that inhibits the growth of Escherichia coli. These results indicated that rhLF containing antimicrobial activity can be produced in N. benthamiana using the Tsukuba system.
- || Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Review, Journal, IO biomarker: Fragmented antibodies in non-small cell lung cancer: a novel nano-engineered delivery system for detection and treatment of cancer. (Pubmed Central) - Jul 15, 2023
When combined with functional nanocarriers, antibody fragments can target cancer cells while offering improved efficacy and fewer off-target effects. We discuss current topics of interest including anti-CTLA-4 mAbs, Talactoferrin alfa (TLF), and the CYFRA 21-1 biomarker, with brief insights into its novel detection system.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: In vitro prebiotic activity of rhLf and galactooligosaccharides on infant intestinal microbiota. (Pubmed Central) - Apr 19, 2023
despite the importance of the batch culture fermentation technique in uncovering the prebiotic activity of food ingredients, it is not useful for detecting the prebiotic nature of Lf due to its nature as a protein. Thus, Lf maybe shows its prebiotic activity on the gut microbiota through other mechanisms.
- || Apolactoferrin (talactoferrin alfa) / Agennix
Review, Journal: Colostrum Proteins in Protection against Therapy-Induced Injuries in Cancer Chemo- and Radiotherapy: A Comprehensive Review. (Pubmed Central) - Jan 22, 2023
Apart from reducing side effects of the applied therapeutics, radiation and surgical procedures, BC and LF augmented their efficacy and improved the wellness of patients. In conclusion, colostrum and colostrum proteins, preferably administered with probiotic bacteria, are highly recommended for inclusion to therapeutic protocols in cancer chemo- and radiotherapy as well as during the surgical treatment of cancer patients.
- | etoposide IV / Generic mfg.
Journal: Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells. (Pubmed Central) - Oct 29, 2022
The calculated dose reduction index indicated that the combination treatment reduced a 10-fold of etoposide dose to achieve the same anticancer effect. Our data demonstrate that rhLf enhanced the anticancer activity of etoposide and diminished etoposide-induced cytotoxic effect in endothelial cells.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitis. (Pubmed Central) - May 12, 2022
Here, we report an effective strategy to fabricate silk sericin nanospheres systems for the delivery of recombinant human lactoferrin (SS-NS-rhLF)...The fabricated SS-NS-rhLF showed identical spherical morphology, stable structure, sustainable rhLF release, efficient cell uptake and negative charge in an environment of pH above 5.5, thus realized the specific targeting to the positively charged colonic sites to treat UC mice through oral administration. The therapeutic effect of SS-NS-rhLF with a low rhLF dose in the UC mice was comparable to the high dose of free rhLF treatment in solution form, suggesting that the SS-NS-rhLF is a promising system for colitis treatment.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice. (Pubmed Central) - May 6, 2022
Recombinant human lactoferrin exhibited potential anticancer and immuno-enhancing properties in mice with breast cancer. Co-treatment with rhLF and EPI proved to be a promising strategy in cancer treatment.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Lactoferrin Induces Erythropoietin Synthesis and Rescues Cognitive Functions in the Offspring of Rats Subjected to Prenatal Hypoxia. (Pubmed Central) - Apr 19, 2022
The protective effects of recombinant human lactoferrin rhLF (branded "CAPRABEL™") on the cognitive functions of rat offspring subjected to prenatal hypoxia (7% O, 3 h, 14th day of gestation) have been analyzed...Apo-rhLF injected to rat dams either during pregnancy or nurturing the pups was able to rescue cognitive deficits caused by prenatal hypoxia and improve various types of memory both in young and adult offspring when tested in the radial maze and by the Novel Object Recognition (NOR) test. The data obtained suggested that the apo-form of human LF injected to female rats during gestation or lactation protects the cognitive functions of their offspring impaired by prenatal hypoxia.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Lactoferrin modified by hypohalous acids: Partial loss in activation of human neutrophils. (Pubmed Central) - Mar 24, 2022
Here we compared the effects of recombinant human lactoferrin (rhLTF) and its halogenated derivatives (rhLTF-Cl and rhLTF-Br) on functional responses of neutrophils...Furthermore, all rhLTF forms interfered with PMA- and ionomycin-induced formation of neutrophil extracellular traps. Thus, halogenative modification of LTF is one of the mechanisms involved in modulating a variety of signaling pathways in neutrophils to control their pro-inflammatory activity.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice. (Pubmed Central) - Mar 8, 2022
Increased drug penetration was accompanied by retention of endothelial cell integrity. Immunohistochemistry revealed altered patterns of M1-like and M2-like phenotypic cell localization post infectious challenge, with increased presence of M2-like markers found evenly distributed throughout regions of pulmonary inflammatory foci in rHLF-treated mice.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities. (Pubmed Central) - Feb 3, 2022
Moreover, in ALL cells, rhLf-h-glycan altered cell cycle progression inducing the G2/M phase arrest, and caused apoptotic DNA fragmentation. Overall, our findings revealed that rhLf-h-glycan has potential as an anticancer agent and therefore deserves further in vivo evaluation.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Kinetic investigation of protein adsorption into polyelectrolyte brushes by quartz crystal microbalance with dissipation: The implication of the chromatographic mechanism. (Pubmed Central) - Oct 15, 2021
In this work, we use quartz crystal microbalance with dissipation to in situ investigate adsorption kinetics of γ-globulin and recombinant human lactoferrin on poly(3-sulfopropyl methacrylate) (pSPM) sensors prepared via atom transfer radical polymerization...Furthermore, the influence of buffer pH and salt concentration further validated the ion exchange characteristics of protein adsorption into pSPM brushes. The research provided a variety of in situ evidence of protein binding and conformation evolution in pSPM brushes and elucidated mechanism of protein adsorption in pSPM brushes.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal, IO biomarker: Ameliorative effect of recombinant human lactoferrin on the premature ovarian failure in rats after cyclophosphamide treatments. (Pubmed Central) - Aug 27, 2021
The in vitro treatments of rhLF effectively conferred the toxicity of 4-HC on primary rat GCs. The fertility assessment showed the rhLF treatments up-regulated the offspring's' folliculogenesis, which confirmed the ameliorative role of rhLF on the POF damages via the inhibition of ROS production in GCs.
- | oxaliplatin / Generic mfg.
Journal: The pain-relieving effects of lactoferrin on oxaliplatin-induced neuropathic pain. (Pubmed Central) - Jul 30, 2021
Histopathological analysis of sciatic nerve showed that both rhLf and rhLf-Fc tended to reduce nerve fiber damage, but no significant difference was observed in nerve fiber cross-sectional area. Therefore, it was suggested that rhLf or rhLf-Fc injection could be an option for controlling neuropathic pain, which are side effects of OXL.
- || Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Clinical, Review, Journal: The Role of Recombinant Proteins and Growth Factors in the Management of Diabetic Foot Ulcers: A Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Jul 3, 2021
Overall, there is a greater agreement on the effectiveness of EGF to enhance the healing of diabetic ulcers. Nevertheless, extant evidence is lacking for other agents since few trials have been conducted for most of the growth factors and available studies are heterogeneous in their methodologies.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice. (Pubmed Central) - May 15, 2021
In addition, the cytoprotective role of Lf may be associated with the inhibition of endoplasmic reticulum (ER) stress and inflammation, promotion of autophagy of damaged hepatocytes and induction of up-regulation of hypoxia inducible factor-1α/vascular endothelial growth factor (HIF-lα/VEGF) to facilitate liver function recovery. These findings suggest that recombinant human Lf might be a potential therapeutic agent for mitigating or delaying the pathological process of NAFLD.
- || Apolactoferrin (talactoferrin alfa) / Agennix
Clinical, Journal: Lactoferrin for the treatment of age-associated inflammation - A pilot study. (Pubmed Central) - Apr 13, 2021
We hypothesized that recombinant human Lactoferrin (rhLf) would reduce chronic inflammation of aging...Treatment with rhLf did not significantly alter serum IL6 or sTNFR1 concentrations of older adults. This study may have been underpowered to detect difference, but provided evidence that a larger sample-size could more definitively determine the effect of rhLF on age-associated CI.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Lactoferrin is a dynamic protein in human melioidosis and is a TLR4-dependent driver of TNF-α release in Burkholderia thailandensis infection in vitro. (Pubmed Central) - Sep 12, 2020
Bt growth was quantified in liquid media in the presence of purified and recombinant human lactoferrin...Lactoferrin is produced by blood cells after exposure to Bp and lactoferrin concentrations are higher in 28-day survivors in melioidosis. Lactoferrin induces proinflammatory cytokine production after Bt infection that may be TLR4 dependent.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Development of dairy herd of transgenic goats as biofactory for large-scale production of biologically active recombinant human lactoferrin. (Pubmed Central) - Jul 2, 2020
The high expression level of rhLF achieved in milk of transgenic goats provides a solid basis for developing an efficient and cost-effective downstream processing. The rhLF exhibited a prominent biological activity suggesting it as a promising biopharmaceutical and food supplements.
- || Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Clinical, Review, Journal: Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review. (Pubmed Central) - May 29, 2020
A systematic literature search provided no conclusive evidence of any pharmacologic intervention that has consistently reduced mortality in critically ill patients. Strategies associated with improved or noninvasive mechanical ventilation were associated with reduced mortality.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells. (Pubmed Central) - May 11, 2020
Overall results suggest that rhLf is using the apoptosis pathway as its mechanism to inflict cell death. Findings warranty further evaluation of rhLf as a potential anti-breast cancer drug option.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: In vitro effectiveness of recombinant human lactoferrin and its hydrolysate in alleviating LPS-induced inflammatory response. (Pubmed Central) - Apr 19, 2020
Thus, these functional ingredients could be incorporated in infant foods. In this context, ongoing researches are conducted to clarify this effect whether by using synthetic peptides or by using LPS-sepsis animal.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Effects of recombinant human lactoferrin on calcium signaling and functional responses of human neutrophils. (Pubmed Central) - Apr 10, 2020
The role of calcium signaling seems to be essential for rhLf-induced activation of neutrophils, as Ca-chelators inhibit degranulation response while lectin-induced HO production correlates significantly with cytoplasmic Ca elevation. Taken together, our findings justify that rhLf can activate neutrophil functions in a calcium-dependent manner and hence, can potentiate innate immune responses.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among People Living with HIV Receiving Antiretroviral Therapy. (Pubmed Central) - Feb 25, 2020
P2
There was no significant effect on plasma interleukin-6 and D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe, but did not reduce inflammation and immune activation.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Untargeted metabonomics of genetically modified cows expressing lactoferrin based on serum and milk. (Pubmed Central) - Jan 24, 2020
The results showed that the GM cows were in healthy condition and their milk have improved benefits for customers. The milk from genetic modified cows showed a promising milk source for producing recombinant human lactoferrin (rhLF) for human beings.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: A silkworm based silk gland bioreactor for high-efficiency production of recombinant human lactoferrin with antibacterial and anti-inflammatory activities. (Pubmed Central) - Jul 18, 2019
coli) and Bacillus subtilis. These results show that the middle silk gland of silkworm can be an efficient bioreactor for the mass production of rhLF and the potential application in anti-inflammation and antibacterial.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Expression and characterization of recombinant human lactoferrin in edible alga Chlamydomonas reinhardtii. (Pubmed Central) - Jul 4, 2019
Our data indicated that expression of hLF in C. reinhardtii is feasible and paved a way to commercial production of lactoferrin using edible Chlamydomonas expression system. Abbreviations: atrazine chlorohydrolase gene (atzA); bovine serum albumin (BSA); human LF (hLF); lactoferrin (LF); Luria-Bertani (LB); quantitative reverse transcriptase PCR (qRT-PCR) ; SDS polyacrylamide gel electrophoresis (SDS-PAGE); Tris-acetate phosphate (TAP); western blotting (WB).
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Immunomodulatory properties of human recombinant lactoferrin in mice: Implications for therapeutic use in humans. (Pubmed Central) - Jul 1, 2019
Abbreviations: atrazine chlorohydrolase gene (atzA); bovine serum albumin (BSA); human LF (hLF); lactoferrin (LF); Luria-Bertani (LB); quantitative reverse transcriptase PCR (qRT-PCR) ; SDS polyacrylamide gel electrophoresis (SDS-PAGE); Tris-acetate phosphate (TAP); western blotting (WB). Evidence for the potential preventive or therapeutic utility of rhLF in patients with impaired immune reactivity has been demonstrated.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Journal: Large-scale production of recombinant human lactoferrin from high-expression, marker-free transgenic cloned cows. (Pubmed Central) - May 15, 2019
A total of 400-450 g of rhLF protein, which shows similar enzymatic activity to natural hLF in iron binding and release, can be purified on a large scale from >100 L of milk per day. Our results suggested that transgenic bovine mammary bioreactors have the potential for large-scale protein production.
- | Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial completion, Monotherapy, Metastases: Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: Agennix
Our results suggested that transgenic bovine mammary bioreactors have the potential for large-scale protein production. No longer recruiting --> Completed
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial termination, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
No longer recruiting --> Completed Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor.
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Enrollment change, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor. N=20 --> 4
- ||||||| Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial completion: FORTIS-M: Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 12, 2012
P3, N=742, Completed, Sponsor: Agennix
N=20 --> 4 Active, not recruiting --> Completed
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
New P1 trial, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Feb 5, 2012
P1, N=4, Terminated, Sponsor: Stanford University
- || Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial suspension: OASIS: Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis (clinicaltrials.gov) - Feb 1, 2012
P2/3, N=1280, Suspended, Sponsor: Agennix
Active, not recruiting --> Completed Recruiting --> Suspended